These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1281145)

  • 1. The prognostic value of prostate-specific antigen and prostatic acid phosphatase in serum of patients with prostate cancer after orchidectomy.
    Dutkiewicz S; Stawarz B; Lypka A; Zieliński H
    Int Urol Nephrol; 1992; 24(4):409-16. PubMed ID: 1281145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
    Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
    Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of prostate-specific antigen and prostatic acid phosphatase in the management of prostatic cancer.
    Turkes A; Nott J; Turkes AO; Griffiths K
    Am J Clin Oncol; 1988; 11 Suppl 2():S77-9. PubMed ID: 2468280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of prostate-specific antigen minimum after orchidectomy in patients with stage C and D prostatic carcinoma.
    Riedl CR; Huebner WA; Mossig H; Ogris E; Pflueger H
    Br J Urol; 1995 Jul; 76(1):34-40. PubMed ID: 7544202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
    Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
    Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer?
    Omacini S; Mione R; Barichello M; Santucci Delli Ponti U; Bolgan A; Contemori GP; Petracco S; Capitanio G; Donisi PM; Gion M
    Eur Urol; 1992; 21 Suppl 1():108-10. PubMed ID: 1385128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer.
    Waehre H; Wanderaas EH; Paus E; Fosså SD
    Eur Urol; 1992; 22(1):33-8. PubMed ID: 1385143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
    Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
    Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen and prostatic acid phosphatase in the detection of early prostate cancer and in the prediction of regional lymph node metastases.
    Wirth MP; Frohmüller HG
    Eur Urol; 1992; 21(4):263-8. PubMed ID: 1281102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].
    Petrone U; Gaspari G; Marascia G; Magnocavallo N; Petrone D; Tucci C
    Minerva Urol Nefrol; 1990; 42(2):73-5. PubMed ID: 1697431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical and prognostic value of inversion of the PSA/PAP ratio in prostatic cancer].
    Morote Robles J; Lorente JA; Reig C; López Pacios MA; de Torres JA; Soler Roselló A
    Actas Urol Esp; 1994 May; 18(5):559-61. PubMed ID: 7521563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements.
    Shih WJ; Gross K; Mitchell B; Collins J; Wierzbinski B; Magoun S; Ryo UY
    J Natl Med Assoc; 1992 Dec; 84(12):1049-50. PubMed ID: 1284282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
    Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC
    Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
    Hetherington JW; Siddall JK; Cooper EH
    Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
    Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditions associated with normal levels of prostate-specific antigen and elevation of prostatic acid phosphatase.
    Lloyd AJ; Formby MR
    Am J Clin Oncol; 1992 Dec; 15(6):487-9. PubMed ID: 1280403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
    Csapo Z; Brand K; Walther R; Fokas K
    J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time.
    Akimoto S; Masai M; Akakura K; Shimazaki J
    Eur Urol; 1995; 27(3):207-12. PubMed ID: 7541360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
    Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
    Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen as a marker of adenocarcinoma of prostate.
    Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K
    Urol Res; 1989; 17(4):245-9. PubMed ID: 2475959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.